MICROVISION, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MICROVISION, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jan 31, 2023 | $2.30M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | $0 | Mar 2, 2023 |
| FY2022 | Sep 30, 2022 | $0 | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | $314.0K | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | $350.0K | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | $557.0K | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $718.0K | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | $746.0K | Mar 2, 2023 |
| FY2022 | Mar 31, 2021 | $479.0K | Mar 2, 2023 |
| FY2022 | Dec 31, 2020 | $395.0K | Mar 2, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $4.70M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $7.26M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $664.0K | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $2.50M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $3.09M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $8.89M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $17.61M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $9.63M | Mar 6, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.34M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($2.83M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $4.49M | Mar 4, 2026 |
| FY2022 | Dec 31, 2022 | ($33.0K) | Mar 2, 2023 |
| FY2022 | Sep 30, 2022 | ($45.0K) | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | $296.0K | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | $346.0K | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | $509.0K | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $728.0K | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | $777.0K | Mar 2, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($94.98M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($96.92M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($82.84M) | Mar 4, 2026 |
| FY2024 | Jan 31, 2023 | $3.90M | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | ($13.48M) | Mar 2, 2023 |
| FY2022 | Sep 30, 2022 | ($12.85M) | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | ($13.60M) | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | ($13.17M) | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | ($12.63M) | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | ($9.38M) | Mar 2, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($82.83M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($85.52M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($88.88M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($53.89M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | ($43.87M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($13.62M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | ($26.47M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($27.22M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($25.48M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($16.46M) | Feb 23, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.72M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $49.02M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $56.71M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $30.41M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $24.11M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $9.84M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $18.66M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $24.67M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $15.10M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $12.13M | Feb 23, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.33M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $29.35M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $36.69M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $24.04M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $22.26M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $5.92M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $8.13M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $9.52M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $10.16M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $8.74M | Feb 23, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($58.72M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($68.54M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($67.09M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($38.02M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | ($29.40M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($16.08M) | Mar 2, 2023 |
| FY2020 | Dec 31, 2019 | ($24.04M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($22.57M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($15.48M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($14.82M) | Feb 23, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $679.0K | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $374.0K | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $1.94M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $4.36M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $2.49M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $402.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $745.0K | Mar 1, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.12M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $121.16M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $129.64M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $115.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $130.23M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $21.01M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $11.84M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $23.03M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $29.77M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $20.11M | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.57M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $72.39M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $33.83M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $25.26M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $17.47M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $12.00M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $15.81M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $18.92M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $19.68M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $12.63M | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.55M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $48.77M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $95.80M | Mar 4, 2026 |
| FY2025 | Dec 31, 2022 | $89.74M | Mar 4, 2026 |
| FY2024 | Dec 31, 2021 | $112.75M | Mar 26, 2025 |
| FY2023 | Dec 31, 2020 | $9.01M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | ($3.98M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2018 | $4.12M | Mar 1, 2022 |
| FY2019 | Dec 31, 2017 | $10.09M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $13.94M | Mar 6, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($957.26M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($862.28M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($765.37M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($682.52M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($629.43M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($586.23M) | Mar 1, 2022 |
| FY2014 | Dec 31, 2014 | ($468.83M) | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | ($450.71M) | Mar 16, 2015 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.36M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $54.49M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $45.17M | Mar 4, 2026 |
| FY2022 | Jan 31, 2023 | $18.50M | Mar 2, 2023 |
| FY2024 | Dec 31, 2022 | $20.54M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $82.65M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $16.86M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $5.84M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $13.77M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $16.97M | Mar 6, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.21M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $33.00M | Mar 4, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 4, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 2, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 4, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Mar 2, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 2, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 306.51M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 224.99M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 194.74M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 170.50M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 164.36M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 152,926 | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 125.80M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 100.11M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 78.60M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 68.09M | Feb 23, 2018 |